Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry

Biomedical Chromatography

Volumn 22, Issue 7, 2008, Pages 770-778

  Zhang, Guodong ^a   Terry, Alvin V ^b   Bartlett, Michael G ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Brain tissue; LC MS MS; Matrix effect; Plasma; Ziprasidone

Indexed keywords

BODY FLUIDS; BRAIN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; RATS; TISSUE;

ANTIPSYCHOTIC DRUG; BRAIN HOMOGENATES; BRAIN TISSUE; LC-MS-MS; LC.MS/MS; LOWER LIMITS OF QUANTITATIONS; MATRICES EFFECT; RAT PLASMA; RATS BRAIN; ZIPRASIDONE;

POSITIVE IONS;

MIDAZOLAM; ZIPRASIDONE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FREEZE THAWING; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT;

RATTUS;

EID: 48349124047     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.999     Document Type: Article

References (20)

1. Al-Dirbashi OY, Aboul-Enein HY, Al-Odaib A, Jacob M and Rashed MS. Rapid liquid chromatography-tandem mass spectrometry method for quantification of ziprasidone in human plasma. Biomedical Chromatography 2006; 20: 365.
2. Aravagiri M, Teper Y and Marder SR. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharmaceutics and Drug Disposition 1999; 20: 369.
3. Aravagiri M, Marder SR and Pollock B. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. Journal of Chromatography B 2007; 847: 237.
4. Greenberg WM and Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Reviews 2007; 13: 137.
5. Janiszewski JS, Fouda HG and Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. Journal of Chromatography B: Biomedical Application 1995; 668: 133.
6. Janiszewski J, Schneider P, Hoffmaster K, Swyden M, Wells D and Fouda H. Automated sample preparation using membrane microtiter extraction for bioanalytical mass spectrometry. Rapid Communications in Mass Spectrometry 1997; 11: 1033.
7. King R, Bonfiglio R, Fernandez-Metzler C, Miller-Stein C and Olah T. Mechanistic investigation of ionization suppression in electrospray ionization. Journal of American Society of Mass Spetrometry 2000; 11: 942.
8. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019.
9. Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G and Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. British Journal of Clinical Pharmacology 2000; 49(suppl. 1): 15S.
10. Prakash C, Kamel A, Gummerus J and Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metabolism and Disposition 1997; 25: 863.
11. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ and Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology 2000; 49(suppl. 1): 35S.
12. Schmidt AW, Lebel LA, Howard HR Jr and Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Europe Journal of Pharmacology 2001; 425: 197.
13. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR and Lowe JA 3rd. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology and Experimental Therapeutics 1995; 275: 101.
14. Srinivas NR. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomedical Chromatography 2006; 20: 383.
15. Suckow RF, Fein M, Correll CU and Cooper TB. Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. Journal of Chromatography B 2004; 799: 201.
16. Terry AV Jr, Gearhart DA, Mahadik SP, Warsi S, Davis LW and Waller JL. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors. Neuroscience 2005; 136: 519.
17. Terry AV Jr, Gearhart DA, Mahadik SP, Warsi S and Waller JL. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 2006; 140: 1277.
18. Wilner KD, Demattos SB, Anziano RJ, Apseloff G and Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. British Journal of Clinical Pharmacology 2000; 49(suppl. 1): 43S.
19. Zhang G, Terry AV Jr and Bartlett MG. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Communications in Mass Spectrometry 2007a; 21: 920.
20. Zhang G, Terry AV Jr and Bartlett MG. Sensitive liquid chromatography/ tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. Journal of Chromatography B 2007b; 858: 276.